MEDTIDE (03880) disclosed its February 2026 monthly return, confirming that the company’s total issued share capital remained at 141.80 million shares. Of these, 73.60 million are H shares and 68.20 million are unlisted shares.

No changes were reported in treasury shares, public float status, share options, warrants, convertibles, or other plans to issue new shares. The company restated that as of 28 February 2026, the minimum public float requirement of 25% for its H shares has been met. The filing was submitted on 04 March 2026, reflecting no alterations to share structure during the reporting period.